Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone281-863-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$63.21 million
Profitability
Miscellaneous
Employees202
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions
What is Lexicon Pharmaceuticals' stock symbol?
Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
How were Lexicon Pharmaceuticals' earnings last quarter?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Wednesday, July, 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.13. The biopharmaceutical company earned $9.68 million during the quarter, compared to the consensus estimate of $28.52 million. The firm's quarterly revenue was down 29.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.33) earnings per share. View Lexicon Pharmaceuticals' Earnings History.
When is Lexicon Pharmaceuticals' next earnings date?
What price target have analysts set for LXRX?
7 equities research analysts have issued twelve-month price targets for Lexicon Pharmaceuticals' stock. Their predictions range from $3.00 to $17.00. On average, they anticipate Lexicon Pharmaceuticals' stock price to reach $6.75 in the next year. This suggests a possible upside of 108.3% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.
What is the consensus analysts' recommendation for Lexicon Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lexicon Pharmaceuticals.
What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (7/3/2019)
- 2. Needham & Company LLC analysts commented, "Lexicon reported 1Q19 U.S. Xermelo sales of $6.7M, below our $8.0M est. Mgmt reiterated 2019 guidance for 20+% y/y U.S. sales growth. Sanofi and Lexicon announced Zynquista approval for by EMA 4/26/19. Lexicon is entitled to a milestone payment in 2Q19 tied to the approval, which we estimate to be around $30M. Discussions w/ FDA around CRL in T1D are planned. No guidance on timing. We previously removed the revenue stream from our model. The first of several Phase 3 T2D trials are expected to generate results beginning in 2Q19 (metformin combination first). We believe the stock is likely to become more attractive if Zynquista is sufficiently differentiated from SGLT2 drugs in T2D, particularly around renal impairment. Maintain HOLD." (5/2/2019)
Has Lexicon Pharmaceuticals been receiving favorable news coverage?
News coverage about LXRX stock has been trending neutral this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Lexicon Pharmaceuticals.
Are investors shorting Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 9,670,000 shares, an increase of 9.3% from the August 30th total of 8,850,000 shares. Based on an average daily trading volume, of 2,490,000 shares, the short-interest ratio is currently 3.9 days. Currently, 9.4% of the company's shares are sold short. View Lexicon Pharmaceuticals' Current Options Chain.
Who are some of Lexicon Pharmaceuticals' key competitors?
Some companies that are related to Lexicon Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), BELLUS Health (BLUSF), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), Turning Point Therapeutics (TPTX), Zymeworks (ZYME), Innoviva (INVA), Esperion Therapeutics (ESPR), ArQule (ARQL), Theravance Biopharma (TBPH) and Dicerna Pharmaceuticals (DRNA).
What other stocks do shareholders of Lexicon Pharmaceuticals own?
Who are Lexicon Pharmaceuticals' key executives?
Lexicon Pharmaceuticals' management team includes the folowing people:
- Mr. Lonnel Coats, Pres, CEO & Director (Age 54)
- Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 54)
- Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 56)
- Dr. Praveen Tyle, Exec. VP of R&D (Age 59)
- Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 60)
How do I buy shares of Lexicon Pharmaceuticals?
Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Lexicon Pharmaceuticals' stock price today?
One share of LXRX stock can currently be purchased for approximately $3.24.
How big of a company is Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals has a market capitalization of $344.31 million and generates $63.21 million in revenue each year. The biopharmaceutical company earns $-120,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.View Additional Information About Lexicon Pharmaceuticals.
What is Lexicon Pharmaceuticals' official website?
How can I contact Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.
MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
